Anavex Life Sciences Corp (AVXL)

[falconer66a]

My Scientific Reasons....

Do you think the biologists who thought the plaque theory was the way to go would have said any different when first reviewing their theory?

Good question, especially what it sets me up for.

Of course, your question is not really anything about scientists who endorsed the plaque theory for the etiology, cause of Alzheimer’s disease — which is now proven wrong. Your question, clearly stated, would have been: Okay, much of the science and medical communities bought into the plaque theory of the cause of Alzheimer’s and have held to it for many years. But, today, strong evidence continues to accumulate that although waste proteins, such as beta-amyloids and tau tangles are found in brains with Alzheimer’s, those proteins are not the actual root cause of the disease. Therefore, could the same thing happen with Anavex’s sigma-1 receptor activation process? Isn’t your AVXL position still at risk, as Anavex science is not yet proven or accepted by the larger science and investment communities?

The answer to that question is, No. The waste protein explanation for Alzheimer’s has been tested for well over at decade, with various new drug candidates in many multi-billion dollar clinical trials. Those monoclonal antibodies have all failed. Chemically inducing the immune system to clear waste proteins from the central nervous system simply won’t work. And even if it did, legacy symptoms of Alzheimer’s would persist. Monoclonal antibodies do not restore normative cellular processes; blarcamesine does.

Simply, as confirmed by the dozens of clinical tests of blarcamesine, in both murines (lab rodents) and actual humans, blarcamesine has never been a clinical failure. Symptomatic improvements have occurred in every clinical trial. And, unlike monoclonal antibodies and other drugs acting in the central nervous system, blarcamesine has never induced adverse events, side effects of any obviating consequence. The drug is uniquely safe in the CNS.

So, yes, I’m confident in my now-completed accumulation of Anavex shares. Blarcamesine is no longer a theory or hypothesis; as the clinical data soon to be released will confirm. For the treatment (and prophylaxis) of CNS diseases, everything changes after that.